Pfizer (PFE) Q1 results:
Revenues: $12,028M (-8.3%); Biopharma: $10,007M (+10.6%); Upjohn: $2,022M (-37.1%).
Q1 revenues included an estimated net favorable impact of ~$150M, or 1%, due to COVID-19.
Internal Medicine: $2,332M (+9%); Oncology:
$2,435M (+24%); Hospital: $2,012M (+1%); Vaccines: $1,611M; Inflammation
& Immunology: $978M (-6%); Rare Disease: $639M (+36%).
Key Product Sales: Eliquis: $1,300M (+29%);
Ibrance: $1,248M (+10%); Prevnar 13/Prevenar 13 : $1,450M (-2%);
Xeljanz: $451M (+7%); Enbrel: $347M (-23%); Sutent: $205M (-12%);
Inlyta: $169M; Xtandi alliance revenues: $209M (+25%); Chantix/Champix:
$270M (-1%); Lyrica: $357M (-70%); Lipitor: $405M (-35%); Norvasc: $197M
(-34%); Vyndaqel/Vyndamax: $231M.
Net Income: $3,401M (-12.4%); EPS: $0.61 (-10.3%); non-GAAP Net Income: $4,514M (-7.7%); non-GAAP EPS: $0.80 (-5.9%).
2020 Guidance: Revenues: $48.5B – 50.5B (unch); non-GAAP EPS: $2.82 – 2.92 (unch).
Shares are up 2% premarket.
Previously: Pfizer EPS beats by $0.09, beats on revenue (April 28)
https://seekingalpha.com/news/3565170-pfizer-eliquis-sales-up-29-guidance-affirmed
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.